Pharming Group N.V. Files 6-K with Press Release

Ticker: PHAR · Form: 6-K · Filed: 2025-11-06T00:00:00.000Z

Sentiment: neutral

Topics: press-release, sec-filing

TL;DR

Pharming Group N.V. dropped a press release on 11/6/25, check the exhibits for deets.

AI Summary

Pharming Group N.V. filed a Form 6-K on November 6, 2025, to furnish a press release dated November 6, 2025. The press release is included as Exhibit 99.1 to this report. No specific financial or operational details from the press release are provided in the filing document itself.

Why It Matters

This filing indicates that Pharming Group N.V. is providing updated information to the SEC, likely containing material news for investors.

Risk Assessment

Risk Level: low — The filing is a routine submission of a press release and does not contain inherently risky information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose of this Form 6-K filing is to furnish a press release dated November 6, 2025, as Exhibit 99.1.

What is the exact date of the press release furnished with this filing?

The press release furnished with this filing is dated November 6, 2025.

What is the Commission File Number for Pharming Group N.V.?

The Commission File Number for Pharming Group N.V. is 001-39822.

Where is Pharming Group N.V.'s principal executive office located?

Pharming Group N.V.'s principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.

Does Pharming Group N.V. file annual reports under Form 20-F or Form 40-F?

Pharming Group N.V. files annual reports under Form 20-F, as indicated by the checkmark next to 'Form 20-F'.

From the Filing

0001828316-25-000049.txt : 20251106 0001828316-25-000049.hdr.sgml : 20251106 20251106060429 ACCESSION NUMBER: 0001828316-25-000049 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20251106 FILED AS OF DATE: 20251106 DATE AS OF CHANGE: 20251106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 251455930 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 a2025q3pressrelease.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2025 Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., dated November 6, 2025. 1 EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: November 6, 2025 2 Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow • Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 • RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribers • Joenja® (leniolisib) third quarter reven ue increased b y 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy • FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026 • Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024 • Generated US$32.0 million in cash flow from operations during the quarter and US$44.0 million year to date • 2025 total revenue guidance raised to US$365 - US$375 million, up from prior US$335 - US$350 million • Leverne Marsh appointed Chief Commercial Officer, effective January 1, 2026&#59; Stephen Toor to step down as CCO at year-end and remain an advisor to the company • Pharming to host a conference call today at 13:30 CET (7:30 am ET) Leiden, the Netherlands, November 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the three mont

View on Read The Filing